| |
Wednesday, October 25, 2023 | 11am ET / 8am PT Increasing diversity in clinical trial populations is necessary to adequately assess the safety and efficacy of new therapies in all patient populations. Join industry expertsto explore: current barriers to diversity of age, gender, race and ethnicity in clinical trials, how real-world data can help bridge the gap, and more. Register now. 
|
|
| By Kevin Dunleavy Pfizer has slashed its 2023 revenue projection by $9 billion because of declining demand for COVID products. The company now expects sales to reach between $58 billion and $61 billion, down from a prior range of $67 billion to $70 billion. Pfizer chalked up most of the decline to a $7 billion decrease in its projection for sales of oral antiviral Paxlovid. The company has also cut its forecast for sales of COVID vaccine Comirnaty by $2 billion. |
|
|
|
By James Waldron Roche has claimed the latest phase 2 readout for its multiple sclerosis drug backs up the BTK inhibitor’s "best in disease" potential by achieving the "holy grail" in biopharma: crossing the blood-brain barrier. |
By Angus Liu Thanks to a new FDA approval for Merck's Keytruda, a continuous immunotherapy regimen around surgery is now available for patients with early-stage non-small cell lung cancer. The drug's label already includes an overall survival win from a key trial. |
By Annalee Armstrong Howard Fillit, M.D., remembers a time when doctors didn’t have a name for the condition that robbed elderly patients of their memory. He’s a geriatrician and neuroscientist, but also the co-founder and chief science officer for the Alzheimer’s Drug Discovery Foundation. |
|
November 14-15, 2023 | Free Virtual Event The Fierce Diversity, Equity, and Inclusion Forum is back again this year and better than ever. We are collaborating with our Fierce Healthcare Editorial Team to expand the topics and audience for this exciting program across two days. Providing a wide range of strategies and best practices for pharma and biotech companies looking to improve their diversity efforts across all areas of their business. Save your seat now! 
|
|
By Angus Liu Bristol Myers Squibb’s Zeposia is no longer the only S1P receptor modulator on the market for ulcerative colitis, thanks to an FDA approval for what appears to be a more effective drug from Pfizer. |
By Annalee Armstrong Biopharmas love to break the news of an M&A deal with a splashy number. Commercial milestones can represent as much as 40% of the so-called earnout potential for a deal—adding up to about $25 billion in potential. But how much of that is actually paid out in the end? |
By Conor Hale Johnson & Johnson MedTech expects to take a $250 million revenue hit before 2026 as it restructures its orthopedics businesses and exits low-performing markets. |
By Zoey Becker On the 1-year anniversary of the official start of the U.S. Adderall shortage, lawmakers inked a letter urging the FDA and DEA for an update detailing the progress the agencies have made in addressing the issue. |
By Nick Paul Taylor Merck KGaA is laying the groundwork for its closely watched multiple sclerosis drug candidate. With phase 3 data imminent, the German drugmaker has begun an awareness campaign to inform physicians about a form of the neurological disease that its treatment may be able to address. |
By Helen Floersh Probiotics could be the key to making universal chimeric antigen receptor T cell therapies work for solid tumors, new research has suggested. |
Fierce podcasts Don’t miss an episode |
| In this week’s episode of “Podnosis,” we delve into how Humana is expanding its reach in senior-focused primary care and home health. Fierce Payer Senior Editor Paige Minemyer caught up with Sanjay Shetty, M.D., president of Humana’s CenterWell segment, to explore why the insurer is placing its bets on primary care and the strategies the company intends to use to achieve its growth ambitions. |
|
|---|
|
|
|
Tuesday, October 31, 2023 | 10am ET / 7am PT This webinar will examine how life science organizations are harnessing the power of innovative technologies to drive growth, improve efficiency, and stay competitive. Join usto gain valuable insights and inspiration to embark on your own transformative journey toward business success. Register now. 
|
|
Whitepaper Uncover the keys to efficient bioprocessing, including how outsourcing quality management can reduce risk, save time and money, and expedite biologics development. Sponsored by: Thermo Scientific™ Production Chemicals and Services |
Whitepaper From trial site feasibility and patient populations to data analysis, generative AI has the potential to revolutionize drug discovery and clinical trial recruitment at both the therapeutic area and indication level. Sponsored by: H1 |
Whitepaper Want to know the Top 5 criteria for selecting the ‘right’ CDMO for pDNA manufacturing? Sponsored by: Syngene |
eBook Learn how to get better results from suboptimal biospecimens for NGS and protein analysis. Sponsored by: Covaris |
Whitepaper Learn more about targeted personas for HCP marketing. Sponsored by: M3 |
eBook Learn how single-cell sequencing speeds up drug development and delivers valuable biological insights. Sponsored by: Single Cell Discoveries |
eBook Emulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
Whitepaper Accelerate drug discovery with high-performance computing (HPC) powered by the cloud Sponsored By: AWS, NVIDIA, and Rescale |
Whitepaper Uncover the keys to efficient bioprocessing, including how outsourcing quality management can reduce risk, save time and money, and expedite biologics development. Sponsored by: Thermo Scientific™ Production Chemicals and Services |
Webinar Embark on an in-depth journey through the pivotal Make-Test-Decide Workflow, where collaboration and data-driven decisions play a paramount role in the intricate landscape of drug discovery. Watch now to learn how cloud implementation fosters accessibility and collaboration, revolutionizing research across locations and companies. Sponsored by: Revvity Signals |
Whitepaper Learn how to help patients with chronic diseases access tailored condition and treatment insights in an environment where they are often inundated with one-size-fits-all messaging that doesn’t align with their individual healthcare journey. Sponsored by: Phreesia Life Sciences |
Research Daiichi Sankyo wanted to create a “single source of truth, the very first place you should go” for content access and rights information. How did they replace five tools with just one? Sponsored by: CCC |
Whitepaper From uncertainty to opportunity – Use cases for life sciences organizations to tap into the power of the metaverse and generative AI Sponsored by: Cognizant |
Whitepaper Economic and regulatory factors are making biopharma supply chains more complex in the EU. This paper explores strategies that biopharma companies can use to better manage complexity, cost, and risk. Presented by: AIM, the supply chain leader for life science entrants and midsize life science companies |
Whitepaper From Assay Development Through Large Molecule Development. Streamline your R&D workflows and gain valuable insights with our Biology Solutions Brochure. Download now to discover how to control your laboratory workflows across various assay techniques, modalities, and data types. Sponsored by: Revvity Signals |
| Edison Ballroom, New York City |
|
|
| |
|
